Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Aptevo Therapeutics Inc (APVO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Aptevo Therapeutics Highlights Key 2019 Priorities

ADAPTIR(TM) Bispecific Antibody Candidates Poised to Progress in Clinical Development

APVO : 1.62 (-2.41%)
Aptevo Therapeutics Collects $3.3 Million In Escrow Funds From Saol Therapeutics

Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today that it has collected $3.3 million in escrow funds from...

APVO : 1.62 (-2.41%)
Aptevo Therapeutics Announces Up To $35 Million Common Stock Purchase Agreement With Lincoln Park Capital

Provides Opportunistic Capital of up to $35 Million to Aptevo During the 36-month Term of the Agreement

APVO : 1.62 (-2.41%)
Aptevo Therapeutics Doses First Patient in Phase 1/1b Clinical Trial of Lead Next-Generation Bispecific Antibody APVO436

Preclinical Data for APVO436 Show Potential Best-in-Class Attributes with Potent T-Cell Directed Tumor Killing and Reduced Cytokine Production Compared to a Competitor Construct

APVO : 1.62 (-2.41%)
United Parcel Service, Endurance International Group, Idera Pharmaceuticals, Aptevo Therapeutics, and Electro Scientific Industries -- Future Expectations, Projections Moving into 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Mercer International Inc. (NASDAQ:MERC),...

SCND : 4.4500 (+2.30%)
ESIO : 29.99 (-0.03%)
EIGI : 7.40 (+0.14%)
APVO : 1.62 (-2.41%)
IDRA : 2.65 (+1.53%)
UPS : 110.87 (-0.83%)
MERC : 14.98 (+0.07%)
Aptevo Therapeutics to Present at the 30th Annual Piper Jaffray Healthcare Conference

Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that management will be presenting at the 30 Annual Piper...

APVO : 1.62 (-2.41%)
Aptevo Therapeutics Reports Third Quarter 2018 Financial Results

Achieves 132% Increase in IXINITY Quarterly Net Revenue Year-Over-Year

APVO : 1.62 (-2.41%)
Alligator Bioscience and Aptevo Therapeutics Present New Preclinical Data for ALG.APV-527 at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting

Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, and Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology...

APVO : 1.62 (-2.41%)
Aptevo Therapeutics Announces Expanded Growth Initiatives for IXINITY

Plans to Introduce 3000 IU IXINITY Assay for Enhanced Patient Convenience

APVO : 1.62 (-2.41%)
Market Trends Toward New Normal in Aptevo Therapeutics, Bottomline Technologies, Allete, Air Lease, The Goodyear Tire & Rubber, and EastGroup Properties -- Emerging Consolidated Expectations, Analyst Ratings

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Aptevo Therapeutics Inc....

EPAY : 47.96 (+1.98%)
APVO : 1.62 (-2.41%)
ALE : 79.39 (+1.85%)
AL : 38.30 (+0.71%)
GT : 18.79 (+1.79%)
EGP : 107.62 (+0.23%)
Wired News - Arrowhead Pharma Presented Preclinical Data on Expanding Pipeline of RNAi Therapeutics for Cardiometabolic Diseases

Stock Monitor: Aptevo Therapeutics Post Earnings Reporting

ARWR : 17.92 (+1.76%)
APVO : 1.62 (-2.41%)
Aptevo Therapeutics Reports First Quarter 2018 Financial Results

Almost Doubles Year-Over-Year IXINITY Quarterly Revenue

APVO : 1.62 (-2.41%)
New Preclinical Data for Novel Immunotherapy Bispecific Candidate ALG.APV-527 Presented by Aptevo Therapeutics and Alligator Bioscience at Prominent Industry Conferences

ALG.APV-527 is Designed to Strategically Target and Engage the Immune System for the Potential Treatment of Multiple Solid Tumor Indications

APVO : 1.62 (-2.41%)
What's in Store for Horizon Pharma (HZNP) in Q1 Earnings?

On Horizon Pharma's (HZNP) first-quarter 2018 earnings call, investors focus will be on the performance of its business units and key products.

ADVM : 3.81 (+8.86%)
HZNP : 23.17 (+1.05%)
APVO : 1.62 (-2.41%)
CLVS : 25.49 (+0.08%)
What's in the Cards for Inovio (INO) This Earnings Season?

Inovio's (INO) most advanced pipeline candidate, VGX-3100's progress remains in focus. However, lack of an approved product in the company's portfolio is a dampener.

ADVM : 3.81 (+8.86%)
ARRY : 23.13 (+4.95%)
APVO : 1.62 (-2.41%)
INO : 3.70 (+0.27%)
What's in Store for Celldex (CLDX) This Earnings Season?

With no approved product in Celldex Therapeutics' (CLDX) portfolio, investor focus is on its immuno-oncology pipeline.

CLDX : 5.86 (+13.35%)
ARRY : 23.13 (+4.95%)
APVO : 1.62 (-2.41%)
BMY : 51.67 (+1.65%)
What's in the Cards for Geron (GERN) This Earnings Season?

With no approved product in Geron's (GERN) portfolio, investor focus continues to remain on its sole pipeline candidate, imetelstat, ahead of the first-quarter earnings release.

ARRY : 23.13 (+4.95%)
APVO : 1.62 (-2.41%)
JNJ : 136.38 (+1.54%)
GERN : 1.47 (+3.52%)
What's in the Cards for Merrimack (MACK) in Q1 Earnings?

Investor focus is likely to remain on Merrimack's (MACK) pipeline updates when it reports first-quarter numbers.

ADVM : 3.81 (+8.86%)
ARRY : 23.13 (+4.95%)
APVO : 1.62 (-2.41%)
MACK : 5.86 (-0.34%)
Aptevo Therapeutics Announces IND Submission for APVO436

New Preclinical Data Presented at AACR Support Best-in-Class Features of APVO436 Highlighting Reduced Cytokine Release and Antibody-Like Half-Life and Manufacturing

APVO : 1.62 (-2.41%)
Report: Developing Opportunities within Natus Medical, Aptevo Therapeutics, Revlon, Silgan, Resources Connection, and TrustCo Bank Corp NY -- Future Expectations, Projections Moving into 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Natus Medical Incorporated...

REV : 26.59 (-0.75%)
APVO : 1.62 (-2.41%)
SLGN : 28.48 (+0.53%)
BABY : 27.32 (+2.05%)
RECN : 17.47 (+2.64%)
TRST : 8.22 (+1.86%)

Van Meerten Stock Picks

SecureWorks - Pick of the Day
My Stock Pick of the Day belongs to the security software company SecureWorks (SCWX).
SCWX -0.33
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar